Henlius to receive a total value of ~$50.5M including a $4.5M up front. The companies collaborated to develop, manufacture, and commercialize Henlius’ 3 products i.e., Hanlikang (rituximab, biosimilar), Hanquyou (trastuzumab, biosimilar) & Hanbeitai (bevacizumab biosimilar) in 16 Latin America countries
Eurofarma to acquire exclusive rights to Hanlikang in 12 countries, Hanquyou in 11 countries, and Hanbeitai in 15 countries including Mexico. Eurofarma will also obtain semi-exclusive rights in Brazil
This collaboration is a testament to Henlius’ product quality, operational strength & continuance of Henlius’ goal of expanding its global footprint. Henlius & Farma de Colombia collaborated to promote Hanlikang’s commercialization in Colombia, Peru, Ecuador & Venezuela
Ref: Henlius | Image: Henlius
